Form 4 for NVNO enVVeno Medical Corp
Accepted 2021-12-02 00:00:00 ET · period of report 2021-11-30 · accession 0001493152-21-030335 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-02 | 2021-11-30 | NVNO | BERMAN ROBERT ANDREW | CEO, Dir | A - Grant | — | +200.0K | 207.7K | +2,585% | — |
| D | 2021-12-02 | 2021-11-30 | NVNO | BERMAN ROBERT ANDREW | CEO, Dir | A - Grant | $0.00 | +349.8K | 349.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-30 | A | A | 200,000 | — | 207,736 | D | — | — | (F1) The Reporting Person was granted 200,000 restricted stock units on November 30, 2021 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The restricted stock units are subject to milestone-based vesting as follows: (i) 50% upon SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) endpoints being achieved, and (ii) 50% upon the Pre-Market Approval of the VenoValve. |
| 2 | Derivative | Stock Options | 2021-11-30 | A | A | 349,781 | $0.00 | 349,781 | D | $6.70 · — to 2031-11-30 | 349,781 Common Stock | (F2) The common stock options were issued to the Reporting Person on November 30, 2021 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2024. |